Surgery – Diagnostic testing – Measuring or detecting nonradioactive constituent of body...
Reexamination Certificate
2001-02-15
2004-01-20
Winakur, Eric F. (Department: 3736)
Surgery
Diagnostic testing
Measuring or detecting nonradioactive constituent of body...
C600S318000, C600S321000
Reexamination Certificate
active
06681127
ABSTRACT:
BACKGROUND OF THE INVENTION
An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid which is accessible to light. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body that is not as accessible, such as blood or intracellular fluid.
Various noninvasive or minimally invasive methods to measure analytes, particularly glucose, have been described. For example, March, U.S. Pat. Nos. 3,958,560 and 4,014,321, discloses a glucose sensor wherein a patient's eye is automatically scanned using a source of light at one side of the cornea. A sensor located at the other side of the cornea detects the light that passes through the cornea. The level of glucose which rotates the plan of polarized light in the aqueous humor of the patient is a function of the amount of radiation detected. However, this sensor system is not necessarily specific or widely applicable to detection of analytes other than glucose, because it does not exploit the use of biological molecules which can detect glucose or other analytes in a body tissue or fluid sample. Biological molecules, as is well known, can provide very specific and sensitive detection reagents for particular analytes.
Schultz, U.S. Pat. No. 4,344,438, discloses a system for monitoring low molecular weight compounds in blood plasma by optical means, which involves a chamber which contains specific receptor sites for the plasma constituent to be analyzed. This system is very invasive, however, because it must be implanted within the blood stream using a hypodermic needle. The system also inherently contains the risks of clotting around the device, obstruction, and other adverse reactions, including immune reactions, general irritation, and foreign body reactions.
BRIEF SUMMAARY OF THE INVENTION
Embodiments of the present invention overcome these disadvantages in the prior art by employing an ophthalmic lens comprising a receptor moiety which comprises an analyte/competitor moiety binding site to detect an analyte in an ocular fluid. Concentration of a wide variety of analytes can be measured using an ophthalmic lens according to embodiments of the invention. Such analytes include, but are not limited to, electrolytes and small molecules (e.g., sodium, potassium, chloride, phenylalanine, uric acid, galactose, glucose, cysteine, homocysteine, calcium, ethanol, acetylcholine and acetylcholine analogs, ornithine, blood urea nitrogen, creatinine), metallic elements (e.g., iron, copper, magnesium), polypeptide hormones (e.g., thyroid stimulating hormone, growth hormone, insulin, luteinizing hormones, chorionogonadotrophic hormone), chronically administered medications (e.g., dilantin, phenobarbital, propranolol), acutely administered medications (e.g., cocaine, heroin, ketamine), small molecule hormones (e.g., thyroid hormones, ACTH, estrogen, cortisol, estrogen, and other metabolic steroids), markers of inflammation and/or allergy (e.g., histamine, IgE, cytokines), lipids (e.g., cholesterol), plasma proteins and enzymes (e.g., complement, coagulation factors, liver function enzymes, heart damage enzymes, ferritin), markers of infection (e.g., virus components, immunoglobulins such as IgM, IgG, etc., proteases, protease inhibitors), and/or metabolites (e.g., lactate, ketone bodies).
REFERENCES:
patent: 3769961 (1973-11-01), Fatt
patent: 4321261 (1982-03-01), Ellis et al.
patent: 4330299 (1982-05-01), Cerami
patent: 4344438 (1982-08-01), Schultz
patent: 4597392 (1986-07-01), Opitz et al.
patent: 5222495 (1993-06-01), Clarke et al.
patent: 5246867 (1993-09-01), Lakowicz et al.
patent: 5341805 (1994-08-01), Stavridi et al.
patent: 5342789 (1994-08-01), Chick et al.
patent: 5352411 (1994-10-01), Khuri
patent: 5356780 (1994-10-01), Robinson et al.
patent: 5383452 (1995-01-01), Buchert
patent: 5433197 (1995-07-01), Stark
patent: 5435307 (1995-07-01), Friauf et al.
patent: 5503770 (1996-04-01), James et al.
patent: 5711915 (1998-01-01), Siegmund et al.
patent: 5820557 (1998-10-01), Hattori et al.
patent: 5830139 (1998-11-01), Abreu
patent: 5854078 (1998-12-01), Asher et al.
patent: 5898004 (1999-04-01), Asher et al.
patent: 6011984 (2000-01-01), Van Antwerp et al.
patent: 6040194 (2000-03-01), Chick et al.
patent: 6120460 (2000-09-01), Abreu
patent: 6152875 (2000-11-01), Hakamata
patent: 6187599 (2001-02-01), Asher et al.
patent: 6197534 (2001-03-01), Lakowicz et al.
patent: 6197928 (2001-03-01), Tsien et al.
patent: 6256522 (2001-07-01), Schultz
patent: 6312393 (2001-11-01), Abreu
patent: 6319540 (2001-11-01), Van Antwerp et al.
patent: 0 236 023 (1987-09-01), None
patent: WO 93/01745 (1993-02-01), None
patent: WO 97/19188 (1997-05-01), None
patent: WO 98/22820 (1998-05-01), None
patent: WO 99/51142 (1999-10-01), None
patent: WO 00/10007 (2000-02-01), None
patent: WO 00/13580 (2000-03-01), None
patent: WO 00/16099 (2000-03-01), None
patent: WO 00/64492 (2000-11-01), None
patent: WO 01/18237 (2001-03-01), None
patent: 02/03855 (2002-01-01), None
Lundgren et al., “A Dynamical Investigation of Acrylodan-Labeled Mutant Phosphate Binding Protein”, Analytical Chemistry, 71 (3), 589-595 (1999).
Komives et al., “Improvement of Optical Fiber Based Biosensors”, Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 12, No. 2,478—479 (1990).
Schauer-Vukasinovic et al., Rational Design of a Calcium Sensing System on Induced Conformational Changes of Calmodium, Journal of the American Chemical Society, vol. 119, No. 45, 11102-11103 (1997).
TV News Reports.
Technology News: MSNBC.COM “Contact Lens Measures Glucose”.
Schultz et al., “Affinity Sensors for Individual Metabolites”, Biotechnology and Bioengineering Symp No. 9, 65-71 (1979).
Schultz et al., “Affinity Sensor: A New Technique for Developing Implantable Sensors for Glucose and other Metabolites”, Diabetes Care, vol. 5 No. 3, May-Jun. 245-253 (1982).
Meadows et al., “Fiber-Optic Biosensors Based on Fluorescence Energy Transfer”, Talanta, vol.35, No. 2, 145-150 (1988).
The Photonics Dictionary, 1996 Book 4, 42nd Edition, pp. D24, D153.
Manual of Skin Diseases, Fifth Edition, Gordon C. Sauer, Md., 1985, pp. 204, 373.
Fm-2 Fluorotron Master Ocular Fluorophotometer, 1994 OcuMetrics, Inc.
Textbook of BioChemistry With Clinical Correlations, Second Edition, Thomas M. Devlin, Ph.D., 1986, pp. 118, 139.
Physical Optics, Third Revised Edition, RObert W. Wood, 1961, pp. 650-651.
Salins et al., “Optical Sensing System for Glucose Based on Genetically Engineered Galactose / Glucose Binding Protein”, Pitcon '99 Book of Abstracts, Mar. 7-12, 747.
Aylott et al., “Development of Fiber Optic Based Glucose Biosensors”, Pitcon '99 Book of Abstracts, Mar. 7-12, 748.
Kremer Matthew J
Winakur Eric F.
LandOfFree
Ocular analyte sensor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ocular analyte sensor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular analyte sensor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3266964